Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Metformin offers cardio benefits over sulfonylureas in diabetes

08.11.2012
A Vanderbilt study examining the impact of the two most commonly prescribed oral diabetes medications on the risk for heart attack, stroke and death has found the drug metformin has benefits over sulfonylurea drugs.

It was important to examine the cardiovascular impact of the more commonly used diabetes drugs after recent controversy surrounded another diabetes medication, rosiglitazone, because it was associated with an increased cardiac risk, said lead author, Christianne L. Roumie, M.D., MPH, assistant professor of Internal Medicine and Pediatrics. Smaller studies pointed to a potential advantage of taking the drug metformin but this study confirms this in a large population.

"We demonstrated that for every 1,000 patients who are using metformin for a year there are two fewer heart attacks, strokes or deaths compared with patients who use sulfonylureas. I think this reinforces the recommendation that metformin should be used as the first medication to treat diabetes," Roumie said.

The researchers looked at the charts of more than 250,000 veterans receiving care in Veterans Health Administration hospitals throughout the United States. The patients were started on oral therapy for their diabetes with either metformin or a sulfonylurea and followed for about a year. Results are in the Nov. 6 issue of Annals of Internal Medicine.

"Both drugs do a good job helping control diabetes and preventing nerve damage and eye disease associated with high sugar levels. We did this study because there was an important knowledge gap about whether metformin was superior to sulfonylureas for prevention of heart disease, stroke and death," said senior author Marie R. Griffin M.D., MPH, professor of Preventive Medicine.

The limitations of the study include that neither patient group was compared with diabetic patients who take no oral medications, and that the veteran patients were mostly men.

Metformin is already the recommended first-line therapy for those needing oral medication to control type 2 diabetes. The most common side effect is stomach upset, which can often be overcome by titrating the dosage up slowly. It has not been recommended that patients with kidney impairment take metformin, so sulfonylureas might be a better choice for those patients.

Roumie said this study suggests it might be prudent to take a second look at those patients who have been taking sulfonylureas to see if a switch to metformin might be recommended.

Craig Boerner | EurekAlert!
Further information:
http://www.vanderbilt.edu

Further reports about: Internal Medicine Medicine Metformin diabetes drug diabetes medication

More articles from Health and Medicine:

nachricht Fiber optic biosensor-integrated microfluidic chip to detect glucose levels
29.04.2016 | The Optical Society

nachricht Got good fat?
27.04.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Winzige Mikroroboter, die Wasser reinigen können

Forscher des Max-Planck-Institutes Stuttgart haben winzige „Mikroroboter“ mit Eigenantrieb entwickelt, die Blei aus kontaminiertem Wasser entfernen oder organische Verschmutzungen abbauen können.

In Zusammenarbeit mit Kollegen in Barcelona und Singapur verwendete die Gruppe von Samuel Sánchez Graphenoxid zur Herstellung ihrer Motoren im Mikromaßstab. D

Im Focus: Tiny microbots that can clean up water

Researchers from the Max Planck Institute Stuttgart have developed self-propelled tiny ‘microbots’ that can remove lead or organic pollution from contaminated water.

Working with colleagues in Barcelona and Singapore, Samuel Sánchez’s group used graphene oxide to make their microscale motors, which are able to adsorb lead...

Im Focus: Bewegungen in der lebenden Zelle beobachten

Prinzipien der statistischen Thermodynamik: Forscher entwickeln neue Untersuchungsmethode

Ein Forscherteam aus Deutschland, den Niederlanden und den USA hat eine neue Methode entwickelt, mit der sich Bewegungsprozesse in lebenden Zellen nach ihrem...

Im Focus: Faszinierender Blick in den Zellkern

Veröffentlichungen in Nature Communications zur DNA-Replikation

Vor jeder Zellteilung muss die Erbsubstanz kopiert werden. Die Startpunkte der DNA-Verdoppelung in Zellen von Menschen und Mäusen haben Wissenschaftler um...

Im Focus: Dauerbetrieb der Tokamaks rückt näher

Aussichtsreiche Experimente in ASDEX Upgrade / Bedingungen für ITER und DEMO nahezu erfüllt

Die ihrer Natur nach in Pulsen arbeitenden Fusionsanlagen vom Typ Tokamak sind auf dem Weg zum Dauerbetrieb. Alexander Bock, Wissenschaftler im...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

VDE|DGBMT veranstaltet Tagung zur patientennahen mobilen Diagnostik POCT

28.04.2016 | Veranstaltungen

Norddeutsche Herztage: 300 Experten treffen sich in Kiel

28.04.2016 | Veranstaltungen

Landwirtschaft und Lebensmittel - Analytische Chemiker: Wächter über Umwelt und Gesundheit

28.04.2016 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

SmartF-IT passt Produktionsprozesse flexibel an

29.04.2016 | Informationstechnologie

Neue Entdeckung im Kampf gegen Krebs: Tumorzellen stellen Betrieb um

29.04.2016 | Biowissenschaften Chemie

Fettreiche Ernährung lässt Gehirn hungern

29.04.2016 | Biowissenschaften Chemie